Knowledge 2024 – Thirdera

Retail’s Digital Revolution: Where Domain Expertise Meets Workflow Intelligence

workflow

The retail landscape is undergoing a transformative shift where customer expectations, operational efficiency, and technological innovation are colliding. Today’s retailers aren’t just looking for software—they’re seeking solutions that empower store associates, streamline operations, and ultimately, enhance the in-store customer experience. According to industry leaders, the future of retail isn’t in call centers or paperwork—it’s on…

Read More

Latest

Business Services
Foundational Excellence Fuels GenAI Success — A Thirdera Generative AI Perspective

In the evolving landscape of enterprise technology, generative AI stands poised to redefine how businesses operate — but only if it’s built on the right foundation. Thirdera, now part of Cognizant, is at the forefront of integrating GenAI into the ServiceNow ecosystem, leveraging their deep research and platform knowledge to develop impactful AI solutions. As…

Read More
Business Services
Cybersecurity Hardening: Thirdera’s Unified Approach to Enterprise Vulnerability Management

In an era where digital ecosystems are sprawling and threat vectors continue to multiply, organizations need more than isolated security fixes—they need holistic hardening strategies. Vulnerability response is no longer just a patch-management task; it now spans infrastructure, cloud, AppSec, SaaS, and even overlooked systems hiding in the shadows. Thirdera’s “Cybersecurity Hardening” offering, currently undergoing…

Read More
Business Services
Better Together: Thirdera and Cognizant Forge a New Era of Enterprise Innovation

In today’s digital-first world, businesses are under pressure to transform faster, smarter, and more strategically than ever. The merger of Thirdera and Cognizant marks a pivotal moment in the ServiceNow ecosystem—one where platform mastery meets industry intelligence. By combining Thirdera’s elite ServiceNow capabilities and talent development engine with Cognizant’s global scale and deep vertical expertise,…

Read More

Latest

ESA
ESA Success Requires Strategy, Infrastructure, and Support Beyond Legislation
April 21, 2025

As education savings accounts (ESAs) gain traction across the United States, the conversation is shifting from policy debates to the complexities of implementation. Fueled by post-pandemic dissatisfaction with traditional school models and a desire for more customizable educational options, ESAs are being adopted in a growing number of states, often under “universal” frameworks. But…

Read More
supply chain data analytics
Supply Chain Data Analytics Fails Without Clean Data, Ventagium Delivers the Fix
April 21, 2025

Supply chain leaders face an overwhelming volume of siloed data across ERPs, TMS platforms, and warehouse systems, yet few know how to align it for smarter decisions. The stakes are rising fast. According to Capgemini’s 2024 report Data: A Powerful Ally in Tackling Scope 3 Emission Reduction Targets, 85% of organizations cite data access…

Read More
cancer immunotherapy
What’s Next in Preclinical Cancer Immunotherapy Research?
April 19, 2025

As the field of cancer immunotherapy rapidly evolves, researchers are turning to next-generation in vitro technologies to replicate the complexities of the tumor microenvironment with unprecedented fidelity. Organoid platforms and ex vivo patient-derived tissue models are transforming how scientists approach preclinical testing, offering deeper mechanistic insights and better predictive power for therapeutic response. With immunotherapies…

Read More
vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More